Welcome to our dedicated page for Zentalis Pharmaceuticals news (Ticker: ZNTL), a resource for investors and traders seeking the latest updates and insights on Zentalis Pharmaceuticals stock.
Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative small molecule therapeutics that target fundamental biological pathways in cancer. Utilizing its proprietary Integrated Discovery Engine, Zentalis aims to identify unique targets and develop novel, potentially best-in-class new chemical entities (NCEs) with differentiated product profiles.
The company's robust pipeline is highlighted by two lead product candidates: ZN-c5 and ZN-c3. ZN-c5 is being developed for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer, while ZN-c3 targets advanced solid tumors and ovarian cancer. Zentalis is also developing azenosertib (ZN-c3), a WEE1 inhibitor, as a monotherapy and in combination with other agents to address multiple tumor types.
Recently, Zentalis announced plans to use the net proceeds from its latest offering to fund ongoing and planned clinical trials, as well as for working capital and other general corporate purposes. The company’s financial strategy is designed to support its operational expenses and capital expenditure requirements through 2026.
The company’s latest financial disclosures highlighted strong clinical data for azenosertib, showing an objective response rate of 36.8% in ovarian cancer and uterine serous carcinoma patients. Azenosertib, currently in multiple clinical trials, demonstrated encouraging efficacy both as a monotherapy and in combination with chemotherapy.
Headquartered in New York and San Diego, Zentalis is collaborating with top financial institutions like Morgan Stanley, Jefferies, and Guggenheim Securities to drive its growth. The company's strong cash position is bolstered by its recent offerings and ongoing support from financial advisors.
Continuing to advance its clinical strategies, Zentalis is focused on its fast-to-market approach for azenosertib, aiming to submit its first NDA in gynecologic malignancies by 2026. Furthermore, Zentalis is leveraging its expertise in cancer biology and medicinal chemistry to explore the potential of protein degraders and other innovative treatment modalities.
Stay updated on Zentalis Pharmaceuticals’ latest developments by visiting their official website or following them on social media platforms such as Twitter and LinkedIn.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the dosing of the first patient in a Phase 2 trial for ZN-c3, an oral WEE1 inhibitor, targeting recurrent uterine serous carcinoma (USC). The FDA indicated that ZN-c3 may pursue an accelerated approval pathway based on the trial's design. This Phase 2 trial aims to evaluate the drug's clinical activity, safety, and pharmacokinetics. USC has a poor prognosis, with survival rates of only 30-50%, highlighting the urgent need for effective therapies. ZN-c3 is positioned as a potentially first-in-class treatment, which could redefine USC care.
Zentera Therapeutics has successfully completed a $75 million Series B financing, led by OrbiMed Advisors Asia and Tybourne Capital Management. The funds will support the clinical development of three oncology candidates from Zentalis Pharmaceuticals (Nasdaq: ZNTL) in China, including WEE1 inhibitor ZN-c3, oral SERD ZN-c5, and BCL-2 inhibitor ZN-d5. Zentera has received four Clinical Trial Applications approved in China and aims to advance its pipeline further. The leadership team expresses confidence in becoming a leading biopharmaceutical company focused on delivering innovative cancer therapies.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) has completed an underwritten public offering, raising approximately $172.9 million by selling 3,565,000 shares at $48.50 each, including 465,000 shares from underwriters' options. This funding will support Zentalis' development of oncology therapeutics targeting cancer pathways. The offering utilized an effective shelf registration statement filed with the SEC on May 4, 2021, with Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities as joint managers.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced the pricing of a public offering of 3,100,000 shares of common stock at $48.50 per share, totaling approximately $150.4 million in gross proceeds. The offering, fully underwritten by Morgan Stanley and others, is set to close on July 1, 2021, pending customary conditions. Additionally, underwriters have a 30-day option to purchase 465,000 extra shares. The shares are offered under an effective shelf registration filed with the SEC on May 4, 2021.
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) has announced a proposed underwritten public offering of $150 million in shares of common stock, all to be sold by the company. Additionally, Zentalis may grant underwriters a 30-day option to purchase up to an additional $22.5 million in shares. The offering is being managed by Morgan Stanley, Jefferies, SVB Leerink, and Guggenheim Securities. This offering follows an effective shelf registration statement filed with the SEC on May 4, 2020. A preliminary prospectus supplement will soon be available on the SEC’s website.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported promising interim data from the Phase 1 trial of ZN-c3, a WEE1 inhibitor, showing increased tumor reduction and durability in heavily pretreated solid tumors. The FDA has identified a potential accelerated approval pathway for ZN-c3 in uterine serous carcinoma (USC), with multiple clinical trials underway including a registrational study. ZN-c3 also received orphan drug and rare pediatric disease designations for osteosarcoma. Concurrently, ZN-c5 shows best-in-class safety and tolerability in breast cancer treatments.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced participation in a fireside chat at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 2:30 p.m. ET. Anthony Sun, MD, Chairman and CEO, along with Melissa Epperly, CFO, will represent the company. Interested parties can access the live webcast through the Investors section of Zentalis' website, with an archived version available post-event. Zentalis focuses on developing small molecule therapeutics targeting cancer biology, including candidates like ZN-c5 and ZN-c3.
Zentalis Pharmaceuticals (Nasdaq: ZNTL) reported encouraging initial results from the Phase 1 trial of its WEE1 inhibitor, ZN-c3, demonstrating single-agent activity and multiple Exceptional Responses in heavily pre-treated cancer patients. The company has entered a clinical collaboration with GSK to explore ZN-c3 in combination with niraparib. For Q1 2021, Zentalis had cash and securities of $298.4 million, but reported a net loss of $50.4 million, up from $16.2 million in Q1 2020 due to increased R&D costs.
Zentalis Pharmaceuticals announced a clinical collaboration with GlaxoSmithKline to evaluate ZN-c3, Zentalis' oral WEE1 inhibitor, in combination with ZEJULA (niraparib) for advanced ovarian cancer. This partnership aims to explore the enhanced potential of ZN-c3 as part of combination therapy, potentially improving patient outcomes. ZN-c3 is currently involved in various trials, with significant preclinical data supporting its efficacy. Over 300,000 women are diagnosed with ovarian cancer annually, highlighting the need for innovative treatments. Zentalis retains full ownership of ZN-c3.
Zentalis Pharmaceuticals announced promising initial data from the Phase 1 trial of ZN-c3, a WEE1 inhibitor, showing Exceptional Responses in patients with advanced solid tumors, including ovarian and colorectal cancer. The recommended Phase 2 dose has been set at 300 mg QD. Out of 55 patients, the treatment was well-tolerated, with manageable side effects primarily Grade 1/2. A webcast event is scheduled for April 12 to discuss these findings further.
FAQ
What is the current stock price of Zentalis Pharmaceuticals (ZNTL)?
What is the market cap of Zentalis Pharmaceuticals (ZNTL)?
What products is Zentalis Pharmaceuticals currently developing?
What is the purpose of Zentalis Pharmaceuticals' recent financial offering?
What is azenosertib and why is it significant?
Where are Zentalis Pharmaceuticals' main operations located?
Who are Zentalis Pharmaceuticals' financial collaborators?
What is Zentalis’ Integrated Discovery Engine?
When does Zentalis plan to submit its first NDA for azenosertib?
What are the recent clinical achievements of Zentalis Pharmaceuticals?
How does Zentalis plan to use its expertise in cancer biology?
Where can one access more information about Zentalis Pharmaceuticals?
